For the risk stratification of indeterminate thyroid nodules

Blog
Contact Us
Payment
Physician Portal

Please visit us at ENDOExpo 2024 (Booth 626)

Visit Us at the ATA 2026 Annual Meeting—Booth #48

View Observational Study

Go Now

LP THY-0288-01-0126

ThyraMIRv2 Provides Insight Into Signaling Pathway Genes

By

ThyGeNEXT®+ThyraMIR®v2 is a unique combination testing platform that utilizes an assessment of the most common mutations associated with all types of thyroid carcinoma and microRNA signatures that provide deep insight into the epigenetic regulation of cancer signaling pathways. The assessment of microRNAs with ThyraMIRv2 enables the testing platform to help rule in malignancy, even in […]

ThyraMIRv2 Provides Insight Into Signaling Pathway Genes Read More »

Indeterminate Thyroid Nodules: Mutations and Risk Stratification

By

Within every thyroid nodule lies a genetic story. Molecular testing helps decode that story by analyzing mutations that can help identify whether the nodule is benign or malignant, and can potentially reduce unnecessary surgeries.  Molecular diagnostic testing platforms, like ThyGeNEXT®+ThyraMIR®v2, provide analyses that include the identification of mutations that help to rule in or diagnose

Indeterminate Thyroid Nodules: Mutations and Risk Stratification Read More »